Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
CA 2448482 C · Owner: White, Peter · Inventors: Archambault, Jacques; White, Peter; Wang, Yong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A crystallizable composition, comprising an PV E2 TAD-like polypeptide of SEQ ID NO.2 , complexed with an inhibitor L. The invention also provides a method for producing the , crystallized HPV E2 TAD-inhibitor complex (HPV E2 TAD-L) comprising: a) mixing purified HPV E2 TAD, contained in a purification buffer with solublized , inhibitor L to , generate a complex solution containing the HPV E2 TAD-L complex; and b) crystallizing , the complex from a) in a crystallization buffer. The invention also provides a method for , producing crystallized apo HPV E2 TAD comprising: a) mixing apo HPV E2 TAD, contained in a purification buffer with a crystallization buffer. X-ray crystal structure …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 12, 2002 and granted December 6, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 12, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 12, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.